Avalo Therapeutics, Inc. - Common Stock AVTX 深 沪
等待开盘 11-03 09:30:00 美东时间
18.03
-0.005
-0.03%
华盛通- 最 高18.50
- 今 开18.27
- 成交量 10.90万股
- 最 低 17.53
- 昨 收 18.035
- 总市值 1445.30万
- 52周最高 19.41
- 市盈率 静 --
- 换手率 13.59%
- 52周最低 3.39
- 委 比 0.00%
- 总股本 80.16万
- 历史最高 22032.00
- 量 比 0.34
- 振 幅 5.38%
- 历史最低 3.39
- 每 手 1
- 风险率 3.36%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
Avalo Therapeutics announced the completion of enrollment in its Phase 2 LOTUS trial for AVTX-009 in adults with hidradenitis suppurativa (HS), enrolling approximately 250 patients, exceeding the target of 222. AVTX-009 is a high-affinity IL-1β inhibitor, and the trial aims to evaluate its efficacy, safety, and tolerability in reducing HS symptoms. The primary endpoint is achieving HiSCR75 at Week 16. The trial's success reflects the significant ...
10-29 11:00
AVITA Medical Welcomes Support for RECELL® in Burns in Australia
澳大利亚医疗用品咨询委员会（MSAC）已推荐将RECELL®纳入医保福利计划，用于治疗成人及儿童的严重急性烧伤。MSAC认可RECELL安全有效，能促进伤口愈合、减少供体部位损伤，并缩短住院时间。RECELL使用患者自身皮肤细胞喷洒治疗，无需大面积移植，减轻疼痛和疤痕。此次推荐适用于成人烧伤面积≥20%、儿童≥10%及面部烧伤患者。
10-28 20:30
AVITA Medical Announces CEO Transition
AVITA Medical announces Cary Vance as Interim CEO and Jan Stern Reed as Lead Independent Director following Jim Corbett's departure. The company expects Q3 2025 revenue of ~$17 million and is seeking a permanent CEO, with Vance considered as a candidate.
10-16 22:15
Avalo Therapeutics Highlights AVTX-009 Potential in New Presentation
Avalo Therapeutics ( ($AVTX) ) has shared an update. On October 10, 2025, Avalo...
10-10 19:28
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
Avalo Therapeutics expanded its leadership team by appointing Taylor Boyd as Chief Business Officer and Ashley Ivanowicz as Senior Vice President, Human Resources. Boyd brings over 15 years of biotech and corporate finance experience, while Ivanowicz has nearly 20 years of HR expertise in the biotech sector. These additions support Avalo’s mission to advance IL-1β therapies, including its Phase 2 trial for AVTX-009 in hidradenitis suppurativa. Th...
10-01 11:00
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09-29 17:07
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
ArriVent BioPharma announced the appointment of Brent S. Rice as Chief Commercial Officer. With over 25 years of experience in biotech and pharma, Rice will lead commercial efforts for firmonertinib, a potential treatment for EGFR mutant NSCLC, and advance the company's ADC portfolio. Previously, Rice served as CCO at Autolus Therapeutics and held leadership roles at Amgen and Juno Therapeutics, demonstrating success in launching therapies and bu...
09-22 20:05
美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
HC Wainwright & Co. Maintains Buy on Avalo Therapeutics, Raises Price Target to $25
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Avalo Therapeutics (NASDAQ:AVTX) with a Buy and raises the price target from $15 to $25.
09-17 23:51
Avalo Therapeutics (AVTX) Gets a Buy from Oppenheimer
In a report released today, Leland Gershell from Oppenheimer reiterated a Buy r...
09-15 19:55
